Tests belzutifan in advanced tumors linked to HIF-2α gene changes
Tests belzutifan in people with advanced pheochromocytoma or pancreatic neuroendocrine tumors.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Ann Arbor, Baltimore, Bethesda, Boston, Chicago, Houston, Iowa City, Los Angeles, Nashville, New York, Philadelphia, St Louis, and Warrenville, United StatesSee the 14 sitesAlso in 21 other countries, 72 sites
- Trial code
- NCT04924075
- EU 2023-504853-11-00
- EudraCT 2020-005028-13
- JRCT2011220024
- Registry title
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 355 people, planned
- Started
- 12 Aug 2021
- Expected to end
- 18 Nov 2032
- Type of study
- Interventional
- Treatments tested
- Belzutifan
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older with advanced pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumor, von Hippel-Lindau disease tumors, advanced wild-type GIST, or advanced solid tumors with HIF-2α related gene changes.
- Age
- At least 12 years; at least 18 years for the von Hippel-Lindau group (Cohort B1).
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic pheochromocytoma/paraganglioma, pancreatic neuroendocrine tumor, advanced wild-type GIST, or advanced solid tumors with HIF-2α related genetic alterations. Von Hippel-Lindau disease with localized tumors.
- Earlier treatment
- People who had chemotherapy, targeted therapy, biologics, or other investigational therapy within 4 weeks of the first dose cannot join. Somatostatin analogs are allowed.
- Biomarker or test result
- Advanced solid tumors need HIF-2α related genetic alterations. The von Hippel-Lindau group needs a diagnosis by a germline (inherited) gene test and/or clinical diagnosis.
Main reasons for not taking part
- Cannot swallow medicine or has a disorder that affects absorption of belzutifan
- Second cancer, unless treatment was completed with no sign of cancer for 2 years
- Pulse oximeter reading below 92% at rest, or needs extra oxygen
- Serious heart disease, such as unstable angina, recent heart attack or bypass, or heart failure Class III or IV
- Life expectancy under 3 months
The registry criteria, word for word
Show all 10 criteriaShow less
Other criteria
- The main inclusion criteria include but are not limited to the following:
- Male and female participants at least 12 years of age (at least 18 years of age for Cohort B1)
- Diagnosis of one of the following: Advanced/metastatic pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumors (pNET), von Hippel-Lindau (VHL) disease associated localized tumors, or advanced wild-type gastrointestinal stromal tumor (wt GIST) or advanced solid tumors with Hypoxia Inducible Factor- 2 alpha subunit (HIF-2α) related genetic alterations
- Cohort B1: VHL Disease-associated tumors:; Have a diagnosis of VHL disease as determined by a germline test locally and/or clinical diagnosis; Must be ≥18 years of age
- Has a life expectancy of at least 3 months; The main exclusion criteria include but are not limited to the following:
- Unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan
- History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- Any of the following: A pulse oximeter reading <92% at rest, or requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure
- Received prior treatment (except somatostatin analogs) with chemotherapy, targeted therapy, biologics, or other investigational therapy within the past 4 weeks of first dose of study intervention
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
- Apart from your pancreatic cancer, have you had another cancer in the last 3 years?
Where in United States
Also in 21 other countries, 72 sites
- University of Michigan (Site 0126)Ann Arbor, United StatesContact: Study CoordinatorTaking people
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics (Site 0108)Baltimore, United StatesContact: Study CoordinatorTaking people
- National Institutes of Health (Site 0125)Bethesda, United StatesContact: Study CoordinatorTaking people
- Massachusetts General Hospital (Site 0111)Boston, United StatesContact: Study CoordinatorTaking people
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center (Site 0130)Chicago, United StatesContact: Study CoordinatorTaking people
- University of Texas MD Anderson Cancer Center (Site 0112)Houston, United StatesContact: Study CoordinatorTaking people
- University of Iowa (Site 0104)Iowa City, United StatesContact: Study CoordinatorTaking people
- Cedars-Sinai Medical Center (Site 0110)Los Angeles, United StatesContact: Study CoordinatorTaking people
- Vanderbilt University Medical Center (Site 0107)Nashville, United StatesContact: Study CoordinatorTaking people
- SCRI Oncology Partners (Site 7000)Nashville, United StatesContact: Toll Free NumberNo longer taking part
- Icahn School of Medicine at Mount Sinai (Site 0123)New York, United StatesContact: Toll Free NumberNo longer taking part
- Penn Medicine: University of Pennsylvania Health System-Heme/Onc (Site 0127)Philadelphia, United StatesContact: Toll Free NumberNo longer taking part
- Washington University-Internal Medicine/Oncology (Site 0124)St Louis, United StatesContact: Toll Free NumberNo longer taking part
- Northwestern Medicine Cancer Center - Warrenville (Site 0134)Warrenville, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
The group in the trial
- BelzutifanTreatment being tested
Belzutifan, 120 mg, oral, once daily (QD) until progressive disease or discontinuation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
- Plain-language title
- Tests belzutifan in advanced tumors linked to HIF-2α gene changesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04924075, who can take part
- Publications
- Belzutifan for Advanced Pheochromocytoma or Paraganglioma.The New England journal of medicine, 2025
- Record updated
- 13 November 2026